KDC-MN-147 – Kodiac biolabs

Plain-language summaryIntrigue 80 / 100

L-DOPA (levodopa) is the immediate precursor to dopamine and the principal Parkinson disease treatment for over 50 years. It crosses the blood-brain barrier (which dopamine itself cannot) and is converted to dopamine by neuronal enzymes. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

46/100

Gold-standard Parkinson’s workhorse with exceptional evidence but almost zero frontier research interest

Look, L-DOPA is about as well-understood as any molecule in clinical pharmacology. The biosynthesis pathway from tyrosine to DOPA to dopamine to norepinephrine has been in every biochemistry textbook since the 1960s, Arvid Carlsson shared a Nobel Prize in 2000 partly for mapping the dopamine deficiency story in Parkinson’s, and carbidopa co-formulation (Sinemet) has been optimized over five decades of clinical use. Thats not a criticism. Its just the reality of where the science stands.

The translational story is as complete as it gets. Multiple phase 3 trials, regulatory approval across essentially every major market, mechanistic confirmation in hundreds of independent labs. The ELLDOPA trial established dose-response relationships. Long-term studies have characterized the motor fluctuation and dyskinesia complications with precision. If what you want is evidence, L-DOPA has more of it than almost any compound in this library. If what you want is an unresolved scientific question to point your lab at, this isnt it.

Here’s where the research conversation actually lives today: continuous intestinal gel delivery systems (Duopa/Duodopa) for reducing off periods, subcutaneous levodopa infusion devices, alpha-synuclein aggregation as an upstream target, LRRK2 inhibition, gene therapy approaches that sidestep the precursor entirely. L-DOPA shows up in that research as a comparator arm or a background medication, not as the compound under investigation. Nobody is running a grant to ask whether L-DOPA works for dopamine-deficient Parkinson’s patients. That question is settled.

We think the bench value is modest but real in a narrow way. If you’re studying dopaminergic circuits, building PD animal models, or interrogating DOPA decarboxylase pharmacology, L-DOPA remains a useful and inexpensive tool. The Mucuna pruriens angle is occasionally cited in supplement literature but adds no meaningful research novelty. As a probe, it’s fine; as a target, there’s essentially nothing left to discover at the level a bench investigator could contribute.

The high evidence and translational scores prevent this from falling into the basement, and honestly that’s appropriate. L-DOPA is important and clinically indispensable. But the Kodiac library exists to surface what’s worth chasing next, and a fully-characterized approved drug that’s been in continuous use for sixty years scores exactly where the rubric puts it: respected, settled, and not the direction we’d point a serious research program.

Novelty: 12
Mechanism promise: 20
In-category differentiation: 48
Evidence quality: 88
Translational signal: 85
Research bench value: 45

Rationale L-DOPA earns high marks on evidence quality and translational signal because it is a definitively effective approved drug with decades of replication, but those same facts make it profoundly uninteresting as a research target: the mechanism is completely mapped, the compound is off-patent and commoditized, and the serious research conversation in dopaminergic biology has moved squarely to managing L-DOPA’s complications rather than L-DOPA itself. No hard cap binds; the raw weighted calculation lands the overall at 46.

Dopamine precursor

The immediate precursor of dopamine and the principal pharmacological treatment for Parkinson disease, FDA-approved in combination with carbidopa.

Abstract

L-DOPA (levodopa, L-3,4-dihydroxyphenylalanine; CAS 59-92-7; molecular formula C9H11NO4; molecular weight 197.19) is the immediate precursor of dopamine in the catecholamine biosynthesis pathway. The compound is FDA-approved in combination with carbidopa (Sinemet) or benserazide for Parkinson disease. Carbidopa inhibits peripheral DOPA decarboxylase (which would otherwise convert most administered L-DOPA to dopamine before reaching CNS), enabling effective central dopamine elevation at lower doses with reduced peripheral adverse events. L-DOPA is the principal symptomatic treatment for Parkinson disease and remains the gold standard despite long-term complications including motor fluctuations and dyskinesia. The compound is also extracted naturally from Mucuna pruriens. Doses are highly individualized; typical Sinemet dosing is 25/100 mg three to four times daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-147Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-147

L-DOPA (Levodopa)

Abstract

Read the full monograph